Gabify Raises $175,000 in Pre-Seed Funding Led by Inflection Point Ventures to advance AI Driven Neurodevelopmental Care in India

▴ Health-tech Startup Gabify
Gabify is a HealthTech startup building India’s first AI-powered platform for early screening and therapy management of speech and neurodevelopmental disorders.

New Delhi, 2nd April 2026: Health-tech Startup Gabify, a platform dedicated to solving neurodevelopmental challenges in children, has raised $175,000 in a pre-seed funding round led by Inflection Point Ventures (IPV). The Company has also been awarded ₹25 lakhs under the Nidhi Seed Support Scheme by GHRTBI (G H Raisoni Technology Business Incubator Foundation), a government-backed initiative that supports early-stage startups with high innovation potential. The capital raised will be strategically deployed towards clinical validation, technology enhancement, and team expansion, key priorities aimed at accelerating growth and building a sustainable revenue model.

 

Gabify is part of the 4th cohort of IPV IdeaSchool, an exclusive cohort-based incubator programme designed for Pre-Seed to Seed-stage startups. Having successfully conducted 5 cohorts so far, the programme has supported a strong pipeline of emerging startups.

Gabify is India's first fully hosted speech and neurodevelopmental condition SaaS ecosystem. The startup has an end-to-end AI screening and therapy platform specifically designed for speech and neurological disorders such as Autism and ADHD. Gabify's use of dual-AI (voice + vision) provides a comprehensive view of the child's speech patterns as well as facial expressions, eye gaze, and behaviours based on 189+ clinically validated criteria that are aligned with DSM-5 and CARS. The system employs a human-in-loop (HITL) approach for clinical validation to review all AI-based clinical outputs to ensure they are accurate and reflect expert professional input. Although the model has been designed for Bharat but has the potential to be scaled globally considering that it is multilingual, low bandwidth, and suited to rural communities.

Commenting on the fund raise, Ankur Mittal, Co-founder, Inflection Point Ventures, says, “Addressing neurodevelopmental challenges at an early stage plays a critical role in shaping a child’s future, yet it remains one of the most underserved areas in the healthcare ecosystem. Gabify is tackling this gap through a strong blend of clinical validation and AI-led innovation, enabling faster and more accurate identification of developmental conditions. Their approach has the potential to significantly reduce diagnosis timelines, improve intervention outcomes, and expand access to quality

 

care for families and clinicians alike. At Inflection Point Ventures, we are excited to support Gabify as they work toward transforming early detection and intervention pathways through scalable, technology-driven solutions, both in India and globally. We look forward to leveraging our network and strategic expertise to help the company accelerate its growth journey.”

Gabify was created to save up to 70% in assessment time, enabling clinicians to handle a higher volume of client patients while keeping the same level of clinical accuracy and delivering quality treatment to clients. Their services have been tested in over 35 preschool/daycare centres throughout India during its private-beta testing phase, laying down a solid foundation in the Indian marketplace. Schools, hospitals, private practices, and non-profits (NGOs) have already begun using Gabify; additionally, through programs such as UNDP Youth Co:Lab, SISF Grant, and International conferences in Madrid, the startup has also received both national & international acclaim. As a result of a clear roadmap for growth, Gabify will positively impact the lives of 1 million children by 2028 through various types of roll-outs - B2B, B2C, CSR-focused rollouts.

Sahil Chopra, Founder & CEO, Gabify says, “Working with Inflection Point Ventures has been a deeply collaborative experience. Beyond capital, IPV brings strategic insight, credibility, and a strong founder-first mindset. Our goal with Gabify is to ensure that no child is left behind simply due to delayed diagnosis or lack of access. We are building technology that empowers clinicians, supports parents, and gives every child a fair chance at early intervention and a better future.”

Gabify is led by a strong founding team with deep expertise across business, clinical practice, and technology. Sahil Chopra, Founder and Chief Executive Officer, brings over 12 years of experience in the startup ecosystem. Prachi Sood, Co-Founder and Chief Medical Officer, is a senior speech therapist with over a decade of clinical practice working with top hospitals, including Max and Fortis. Co-Founder & Chief Technology Officer, Vasyl Leshchuk, is a global CIO/CTO with 15+ years of experience leading and developing AI, Cybersecurity, and IPO-scale technologies at CIENCE and Freightos.

Gabify has been recognized among the Top 10 Startups by DreamDeal, the flagship startup initiative by Anupam Mittal, CEO, People Group.

 

Gabify's strong impact has created a following across the most highly regarded startup platforms in India and outside of India. Gabify received a prestigious Startup Rajasthan Ratna Award from the CEO of MeitY, Government of India for its role in the digital health innovation ecosystem. The Company has also won the OCP Challenge 1.0 and topped the Saksham Accelerator by SACC India at TiEcon Chandigarh and won multiple other cohorts and accelerator programs including TechXpedite. Furthermore, Gabify is now the only startup from India chosen to represent the country at Madrid, highlighting its global relevance. The startup is also a Finalist at the Youth Co:Lab by UNDP and Citi Foundation, representing the most impactful social enterprises around the world.

 

The global market opportunity is estimated at USD 110 billion, growing at ~15% CAGR, including a USD 11 billion serviceable addressable market and a USD 1 billion serviceable obtainable market. Growth is being driven by the rising prevalence of autism, now impacting 1 in 30 children post- COVID, alongside increased AI adoption in healthcare, a shortage of therapists, long wait times in India, and strong government and institutional backing for early intervention and digital health.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026
Fatty Liver Disease: Connecting Metabolic Health With Liver CareNovember 12, 2026
Chronic Kidney Disease: Understanding Risk Assessment and Early MonitoringNovember 12, 2026
Advanced OCTA Diagnostics in Age-Related Macular Degeneration (AMD)November 11, 2026
Advanced Diagnostics in Age-Related Macular Degeneration (AMD): Optical Coherence Tomography Angiography (OCTA)November 11, 2026
PCOS Care in India: Understanding Diagnosis and Long-Term MonitoringNovember 11, 2026
Thyroid Health: Making Sense of Testing and Follow-UpNovember 11, 2026